View all trials
Are you a member? Sign in above to view additional information
  • Study title
    PARC: A Phase II study evaluating the activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory Cancers of childhood
  • Protocol ID
    RG-16-040
  • Disease
    Disease Type Disease Subtype
    All Tumour Types
    Other
  • Eligibility criteria
  • Study Status
    Open
  • Location(s)
    Women and Children's Hospital
    • Centre Study Status:
      Open
    • Notes:
  • Phase
    Phase 1/2
  • Study type
    Treatment
  • Diagnosis stage
    Relapse/refractory
  • Study open date
    29/11/2019
  • Study close date
    31/03/2023
  • Study chair
    Dr Maria Kirby
  • Sponsor
    University of Birmingham
Back to search results